Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Street who wrote (6239)	1/9/2005 1:26:06 PM
From: Peter Goss	Read Replies (1) \| Respond to of 10345

An interpretation of the Nature article abstract I posted, again from YMB: Nature Neuroscience article by: twobookends (43/M/Iowa City) Long-Term Sentiment: Strong Buy 01/09/05 12:01 pm Msg: 513732 of 513748 I have a copy of the Nature Neuroscience article. Though the article is quite complex and difficult to read/interpret, I will do my best and pass along what I can. (I am a scientist/researcher/Ph.D.) The problem/question is that the presence of amyloid in past research has not been associated with cognition/memory impairments, and hence researchers have questionned whether amyloid plays a causal role in memory loss/disruption. It is a data-based experiment with three conditions. 1. 18 rats received monomer amyloid-B injection. 2. 19 rats received oligomer amyloid-B injection. 3. 18 rats with both monomer and oligomer amyloid-B received a oligomer amyloid-B suppressant (an anti-amyloid B antibody, presumably AAB-001, ACC-001, or the like). Results were that learning was impaired with oligomer amyloid-B injections (condition 2) but not with either monomer amyloid-B or the suppressant therapy injections. The learning effect (impairment) was potent but transitory (lasting only 1 day), occured in a way that did not damage the nerve cells, and was preventable/reversible with the anti-amyloid-B antibody. The authors conclude that they have now identified a specific mechanism of cognitive impairment via oligomer amyloid-B. They also suggest that this is good news because a theraputic agent/injection should be able to reverse cognitive decline associated with amyloid before AD neuronal degeneration has a chance to occur. They conclude that the effort to clear oligomer amyloid-B with anti-amyloid-B antibodies provides a means of preventing deterioration of cognitive function. Hope this helps.